Free Trial

Bioventix (LON:BVXP) Sets New 52-Week Low - Time to Sell?

Bioventix logo with Medical background

Key Points

  • Bioventix PLC shares reached a new 52-week low at GBX 2,199 ($29.75) during trading, indicating potential concerns among investors.
  • The company's market capitalization stands at £120.44 million with a price-to-earnings ratio of 14.88 and a relatively low beta of 0.35.
  • Bioventix specializes in sheep monoclonal antibodies for various diagnostic applications, including thyroid and oncology-related testing.
  • Want stock alerts on Bioventix? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Bioventix PLC (LON:BVXP - Get Free Report) shares hit a new 52-week low during trading on Friday . The company traded as low as GBX 2,199 ($29.75) and last traded at GBX 2,300 ($31.12), with a volume of 12733 shares changing hands. The stock had previously closed at GBX 2,325 ($31.46).

Bioventix Trading Down 1.1%

The firm has a market cap of £120.44 million, a price-to-earnings ratio of 14.88 and a beta of 0.35. The stock's 50 day moving average is GBX 2,666.29 and its 200 day moving average is GBX 2,730.05.

About Bioventix

(Get Free Report)

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bioventix Right Now?

Before you consider Bioventix, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.

While Bioventix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir’s Soaring Valuation—Justified or Overhyped?
3 Stocks With Explosive Upside
September Slowdown: 3 Stocks to Buy When the Pullback Comes

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines